Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Rizzo M, Buti S, Fiala O, Incorvaia L, Molina-Cerrillo J, Bourlon MT, Fukuokaya W, Urabe F, Park SH, Mayrhofer K, Pichler R, Niedersuess-Beke D, Taha T, Büttner T, Bamias A, Seront E, Santini D, Stumbo L, Rodriguez-Vida A, Massari F, Monteiro FSM, Soares A, Grande E, Santoni M

Open source

DOI: 10.1007/s11523-026-01238-9
Published: 2026 Jul 29
Container: Targeted oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01238-9,
  title = {Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).},
  author = {Rizzo M and Buti S and Fiala O and Incorvaia L and Molina-Cerrillo J and Bourlon MT and Fukuokaya W and Urabe F and Park SH and Mayrhofer K and Pichler R and Niedersuess-Beke D and Taha T and Büttner T and Bamias A and Seront E and Santini D and Stumbo L and Rodriguez-Vida A and Massari F and Monteiro FSM and Soares A and Grande E and Santoni M},
  year = {2026},
  journal = {Targeted oncology},
  doi = {10.1007/s11523-026-01238-9},
  url = {https://doi.org/10.1007/s11523-026-01238-9}
}

RIS

TY  - JOUR
TI  - Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).
AU  - Rizzo M
AU  - Buti S
AU  - Fiala O
AU  - Incorvaia L
AU  - Molina-Cerrillo J
AU  - Bourlon MT
AU  - Fukuokaya W
AU  - Urabe F
AU  - Park SH
AU  - Mayrhofer K
AU  - Pichler R
AU  - Niedersuess-Beke D
AU  - Taha T
AU  - Büttner T
AU  - Bamias A
AU  - Seront E
AU  - Santini D
AU  - Stumbo L
AU  - Rodriguez-Vida A
AU  - Massari F
AU  - Monteiro FSM
AU  - Soares A
AU  - Grande E
AU  - Santoni M
PY  - 2026
JO  - Targeted oncology
DO  - 10.1007/s11523-026-01238-9
UR  - https://doi.org/10.1007/s11523-026-01238-9
ER  -

APA

M, R., S, B., O, F., L, I., J, M., MT, B., W, F., F, U., SH, P., K, M., R, P., D, N., T, T., T, B., A, B., E, S., D, S., L, S., A, R., F, M., FSM, M., A, S., E, G., & M, S. (2026). Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).. Targeted oncology. https://doi.org/10.1007/s11523-026-01238-9

Source records

pubmed · retrieved 2026-09-26T00:49:28.392Z
europe-pmc · retrieved 2026-09-26T00:49:28.393Z